Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/10/19 → 2/7/23 |
Funding
- Exelixis Inc.: $76,925.00
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
- Ain, Kenneth (PI)